ORA Device Director: Inspection 'Program Alignment' Scheme Not Ready Anytime Soon; Investigator Training, Retention Pose Challenge For FDA
This article was originally published in The Gray Sheet
More details about FDA's new commodity-specific inspectional approach continue to emerge, including news that the Office of Regulatory Affairs is under pressure to train agency investigators while simultaneously dealing with the loss of several highly trained auditors to the agency's device center. All of this comes amid a sign-off process on "program alignment" that will extend all the way to Capitol Hill.
You may also be interested in...
The agency is still working to get an oncology center of excellence off the ground and has other large pending reorganizations to tackle before it may get to creating additional centers intended to break down device, drug and biologic silos.
Agency is still working to get oncology center of excellence off the ground and has other large pending reorganizations that could take precedence.
For medtechs, implementing an ESG strategy will need to become a priority as global rules are being introduced for companies to report ESG data. A panel discussion with medtech ESG leaders at the recent LSX Congress USA conference in Boston outlined some strategies and sustainability goals.